Nirali Shah/npr.org
Apr 22, 2025, 11:06
How immune cell baselines may predict CD22 therapy outcomes in Pediatric Cancer – NCI Center for Cancer Research
NCI Center for Cancer Research shared a post on LinkedIn:
“CD22 CAR T-cell immunotherapy is an effective treatment for several types of cancer, with a recent clinical trial showing a 70% response rate.
Researchers wanted to know more about why 30% of patients’ cancers didn’t respond: the answer may lie in the baseline condition of their immune cells. Read more about this CCR study, led by Nirali Shah, from our Pediatric Oncology Branch.
Learn more about research in our Pediatric Oncology Branch.
Image: Microscopy image of B-cell acute lymphoblastic leukemia.
Credit: iStock.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 23, 2025, 17:07
Jun 23, 2025, 15:18